Key Takeaways
- Revenue reset, not a structural break: Total income fell to Rs. 1,859 crores from Rs. 2,343 crores YoY, driven by the normalization of COVID-era demand and high-base effects, while management frames this as the new baseline from which to measure future growth.
- Input-cost tailwind is building: Material consumption dropped to 39% of sales from 42% QoQ as lower-cost raw materials flow through the P&L, with further stabilization expected in coming quarters.
- The pipeline is broadening beyond generics: Contrast media, peptide building blocks for obesity/diabetes drugs, and custom synthesis phase 2/3 projects are all advancing, though none carry a near-term blockbuster commitment.
- Margins have a credible floor: Management pointed to a steady-state EBITDA margin range of 30%, 35%-40%, supported by process efficiency, yield improvements, and solvent recovery capabilities.
- What to watch next quarter: Whether quarterly revenue begins the promised climb toward Rs. 2,000 crores plus, the pace of raw material cost benefits flowing through, and any customer approvals on peptide building blocks.
Revenue & Margin Dynamics
- Top-line reset: The sharp YoY revenue decline reflects the unwinding of COVID-driven demand that had pulled forward volumes across the industry. Management urged investors to treat the current quarter as a new baseline, saying the last 3-4 years were not normal for any business.
- Material cost relief: Raw material prices are on a downward trend and high-cost inventory procured during the supply-chain crisis has been largely consumed. The 300 bps QoQ drop in material cost as a percentage of sales is the first clear signal of this tailwind.
- Solvent advantage: Divi's has installed equipment to recover and reuse rare solvents like acetonitrile and tetrahydrofuran, insulating it from price swings and potential dumping from China.
- Logistics normalization: Sea freight per container has fallen from Rs. 12,000 back to Rs. 2,000, and shipping space is readily available, removing a cost headwind that had persisted through the supply-chain crisis.
- Forex swing: Forex gain collapsed to Rs. 3 crores from Rs. 56 crores YoY, a mechanical drag on reported earnings that does not reflect operating performance.
Dr. Murali K. Divi: "I think from now whatever growth we are seeing, I think we should start saying, this is 0 and look at how we are going to grow from now."
Custom Synthesis & Contrast Media
- Two large projects in commercial phase: Both large-volume custom synthesis projects have entered commercial production and are gearing up toward full capacity, though management declined to disclose what the products are.
- Contrast media advancing on two fronts: CT contrast media API registrations are under review in multiple countries with customer qualifications underway. MRI contrast media (Gadolinium compounds) process development will be complete by end of this financial year, with filings and commercial launch one year beyond that.
- Phase 2/3 pipeline: Enhanced production capacity in small-volume APIs and reduced lead times are supporting multiple phase 2 and 3 projects, but management refused to give a specific conversion timeline for any single product or customer.
- Molnupiravir is not the story: Management explicitly stated that several opportunities exist in custom synthesis beyond the COVID antiviral, and that no one can predict which quarter a blockbuster may materialize.
Dr. Murali K. Divi: "We are working on number of projects with number of big pharmas in the small molecule segment... we cannot predict in which quarter, which blockbuster may happen."
Generic API & Carotenoid Segments
- Established generics are stable: Products like Naproxen Sodium, Gabapentin, and Dexamethorphan face no material price pressure, and Divi's continues to invest in photochemistry and atom-efficient chemistry to lower costs and maintain leadership.
- Basket expansion is gradual: The company plans to add 2-5 new generic products to its basket each year, a slow but steady broadening of the base.
- Carotenoids running hot: The plant is operating at 90-95% capacity with no price pressures, and additional capacity is being added at Unit-3 because demand exceeds current output. Raw materials for carotenoids are mostly manufactured in-house starting from basic materials like ethylene and propylene, so falling import prices do not directly benefit this segment.
- Ethylene backward integration: Divi's is putting up its own ethylene production plant, further reducing dependence on external suppliers for carotenoid inputs.
Peptide Building Blocks & New Therapies
- A decade-in-waiting opportunity: After a long quiet period following leadership in protected amino acids for T20 projects, peptide building blocks have resurged as a "hot cake" driven by new oral anti-obesity and anti-diabetic drugs that use synthetic liquid-phase peptide chemistry. Requirements are in the hundreds of tons.
- No filing required: Unlike finished APIs, peptide building blocks (protected amino acids, dipeptides, tripeptides, coupling agents) require only customer approval and meeting impurity profile specifications, not regulatory filings. This shortens the path to revenue once qualification is achieved.
- Small-molecule expertise applies: Divi's is expert in small molecules below MW 500. For large peptides with molecular weights in the thousands, the company supplies the building blocks that customers assemble into the final peptide, staying within its core competency.
Dr. Murali K. Divi: "It is not a waiting period because it is only a customer approval and we meeting customer's requirements on the impurity profile and that should lead to the business."
Capex & Capacity Expansion
- Unit-3 greenfield progressing: Phase 1 investment of Rs. 1,500 crores will initially manufacture starting materials, nutraceutical APIs, advanced intermediates, and complex chemistry APIs, freeing up Unit-1 and Unit-2 for new custom synthesis and generic opportunities.
- Kakinada project timeline: Total capex estimated at Rs. 1,200-1,500 crores, with Rs. 700 crores being spent in the immediate near future. The site requires building all infrastructure from scratch. Commercialization for advanced intermediates and KSM is targeted for mid-FY25.
- Carotenoid capacity addition: Additional capacity at Unit-3 is expected online sometime in Q1-Q2 of the next financial year.
- DMF pipeline: Recently filed and about-to-file DMFs over the next 6 months are expected to contribute to growth beyond FY25.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Quarterly revenue trajectory | Move toward Rs. 2,000 crores plus, then Rs. 2,200 crores per quarter | No date; "slow, steady, consistent" |
| Steady-state EBITDA margin | 30%, 35%-40% range | Steady-state (no date) |
| MRI contrast media process readiness | Total process ready for scale-up, customer sampling | End of current financial year |
| MRI contrast media commercial launch | Filings and commercial launch | One year after process readiness |
| Kakinada commercialization | Advanced intermediates and KSM production | Mid-FY25 |
| Carotenoid capacity addition | Additional capacity at Unit-3 online | Q1-Q2 of next financial year |
| Generic product basket expansion | 2-5 new products added each year | Annual, ongoing |
| Growth outlook | "Good growth, a double digit growth" barring COVID or unforeseen incidents | Over the coming years |
Dr. Murali K. Divi: "Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models."
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated total income | ₹1,859 cr, vs ₹2,343 cr in Q1 FY23 |
| Constant currency growth | -29% |
| Material consumption | 39% of sales revenue, vs 42% in Q4 FY23 |
| Profit before tax | ₹492 cr |
| Profit after tax | ₹356 cr |
| Forex gain | ₹3 cr, vs ₹56 cr gain in Q1 FY23 |
| Exports share | 86% of revenue |
| Exports to Europe and US | 67% of revenue |
| Product mix (Generics : Custom Synthesis) | 60:40 |
| Nutraceutical revenue | ₹178 cr |
| Capital work in progress | ₹389 cr, of which Kakinada project is ₹130 cr |
| Cash on books | ₹4,208 cr as of March 31, 2023 |
| Receivables | ₹1,720 cr as of March 31, 2023 |
| Inventories | ₹2,967 cr as of March 31, 2023 |
| Dividend payout | ₹796 cr, scheduled September 2023 |
| Carotenoid plant utilization | 90-95% |
| Unit-3 greenfield project phase 1 investment | ₹1,500 cr |
| Steady-state EBITDA margin guidance | 30%, 35%-40% |